Multiple Myeloma Clinical Trial
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant. The treatment consists of increasing doses of BPX-501 T cell infusions to achieve a clinical response. Rimiducid will be investigated for the treatment of aGvHD after BPX-501 T cell infusion to determine a dose that can mitigate GvHD and preserve the graft versus leukemia effect.
Unmanipulated donor lymphocyte infusion (DLI) is used after stem cell transplantation to treat and prevent relapse, to prevent infections and to establish full donor chimerism. The addition of mature T cells which exhibit a broad repertoire of T cell immunity against viral and cancer antigens, might provide a clinical benefit. However, an expected side effect of the presence of mature T cells is the potential occurrence of acute graft-versus-host disease (aGVHD). BPX-501 contains genetically modified donor T cells that have an inducible safety switch iCasp9 suicide gene. Evidence has emerged that escalating DLI has achieved higher clinical response rate with lower GVHD occurrence. Optimization of DLI dose and schedule as well as strategies of donor T-cell manipulation may lead to the consistent ability to separate GVHD from GvL (graft-versus-leukemia) activity and improve the safety of DLI treatment.
Subjects aged >18yrs and < 65yrs
Clinical diagnosis of one of the following adult hematological malignancies
Other high-risk hematologic malignancies eligible for stem cell transplantation per institutional standard Life expectancy >10 weeks
Evidence of recurrent disease that presents > 100 days or minimal residual disease (MRD) that presents > 30 days after one of the following:
Matched related HSCT
Mismatched related HSCT
Signed patient informed consent;
A minimum genotypic identical match of 4/8 is required, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, and HLA- DRB1
Performance status: Karnofsky score > 50%
Subjects with adequate organ function as measured by:
> 25% donor T-cell chimerism
ANC >1 x 10E9/L
Cardiac: left ventricular ejection fraction at rest must be >45%.
Hepatic: direct bilirubin ≤ 3 x upper limit of normal, or AST/ALT ≤ 5 x upper limit of normal
Renal: creatinine ≤ 2x of ULN for age
Pulmonary: FEV 1, FVC, DLCO (diffusion capacity) > 50% predicted (corrected for hemoglobin)
≥ Grade II acute GVHD or chronic extensive GVHD due to a previous allograft at time of screening;
Active CNS involvement by malignant cells;
Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings). The principal investigator is the final arbiter of this criterion;
Positive HIV serology or viral RNA
Pregnancy (positive serum βHCG test) or breast-feeding;
Subjects of reproductive potential unwilling to use effective forms of birth control or abstinence for a year after transplantation;
Bovine product allergy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
Atlanta Georgia, 30342, United States
Westwood Kansas, 66205, United States
Buffalo New York, 14263, United States
Portland Oregon, 97239, United States
Dallas Texas, 75390, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.